Rankings
▼
Calendar
BIIB Q1 2020 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q1 2020 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$3.5B
+1.3% YoY
Gross Profit
$3.1B
87.1% margin
Operating Income
$1.8B
51.5% margin
Net Income
$1.4B
39.6% margin
EPS (Diluted)
$8.08
QoQ Revenue Growth
-3.7%
Cash Flow
Operating Cash Flow
$1.5B
Free Cash Flow
$1.3B
Stock-Based Comp.
$68M
Balance Sheet
Total Assets
$26.1B
Total Liabilities
$13.6B
Stockholders' Equity
$12.5B
Cash & Equivalents
$2.6B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.5B
$3.5B
+1.3%
Gross Profit
$3.1B
$2.9B
+6.7%
Operating Income
$1.8B
$1.5B
+21.1%
Net Income
$1.4B
$1.4B
-0.7%
Revenue Segments
MS Product Revenues
$2.1B
58%
SPINRAZA
$565M
15%
TYSABRI product
$522M
14%
Interferon
$466M
13%
Geographic Segments
UNITED STATES
$1.6B
55%
Non-US
$1.3B
45%
← FY 2020
All Quarters
Q2 2020 →